Glucagon-like peptide 1 treatment reverses vascular remodelling by downregulating matrix metalloproteinase 1 expression through inhibition of the ERK1/2/NF-κB signalling pathway
Sign Up to like & getrecommendations! Published in 2020 at "Molecular and Cellular Endocrinology"
DOI: 10.1016/j.mce.2020.111005
Abstract: In addition to serving as an incretin-based treatment of type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 (GLP-1) can also reverse cardiovascular diseases caused by vascular remodelling. However, a detailed mechanism underlying how GLP-1 reverses… read more here.
Keywords: vascular remodelling; glucagon like; matrix metalloproteinase; reverses vascular ... See more keywords